Search Results

JBS-LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.

JBS-LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected positive findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends a review of those images. Images can be previewed through a mobile application. JBS-LVO is intended to analyze terminal ICA and MCA-M1 vessels for LVOs.

Images that are previewed through the mobile application are compressed and for informational purposes only. They are not intended for diagnostic use beyond notification. The JBS-LVO device does not alter the original medical image. Notified clinicians are responsible for viewing non-compressed images on a diagnostic viewer and engaging in appropriate patient evaluation and relevant discussion with a treating physician before making care-related decisions or requests. JBS-LVO is limited to the analysis of imaging data and should not be used in-lieu of full patient evaluation or relied upon to make or confirm a diagnosis.

Limitations:
The device does not process scans containing metallic artifacts.

JBS-LVO is a radiological computer aided triage and notification (CAD) software package compliant with the DICOM standard. IBS-VV is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to analyze computed tomography angiography (CTA) images for findings suggestive of a suspected large vessel occlusion (LVO) and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Specifically, JBS-LVO is optimized to evaluate occlusions of the intracranial carotid artery (ICA) and proximal middle cerebral artery (MCA-M1 segment). It is important to clarify that this quantification is solely used within the device's Al module to facilitation process. The output provided to heathcare professionals is stiritly a flag indicating the presence (positive) of an LVO, in accordance with regulatory guidelines.

JBS-LVO is a combination of software modules that allow for detection and notification of patients with a suspected LVC. JBS-LVO consists of an algorithm and mobile application software module.

The JBS-LVO Image Analysis Algorithm (LVO Detection Algorithm) is a locked, artificial intelligence (Al) software algorithm utilizing convolutional neural network (CNN) that analyzes CTA images of the brain for a suspected LVO. The LVO Detection Algorithm is hosted on the ILK-server and analyzes applicable CTA images of the brain that are acquired on CT scanners and are automatically transmitted to the ILK-server. Upon detection of a suspected LVO, the LVO notification module sends a notification of the suspected finding.

The JBS-LVO notification functionality enable medical professionals and clinicians to preview compressed and informational images through via mobile application notification. Image viewing through the mobile application interface is for informational purposes only and is not for diagnostic use.

Here's a breakdown of the acceptance criteria and the study proving the device meets them, based on the provided text:

Acceptance Criteria and Device Performance

1. Table of Acceptance Criteria and Reported Device Performance

Notes:

• The document implies that the sensitivity and specificity acceptance criteria were "exceeded," suggesting a >80% threshold was the minimum.
• The AUC is reported as a performance metric, indicating its importance, even if a specific numerical acceptance criterion wasn't explicitly listed alongside the other two.
• The CTA to notification time criterion is established by comparison to a reference predicate device (Rapid LVO, K221248).

Study Details

2. Sample Size Used for the Test Set and Data Provenance

• Test Set Sample Size: Not explicitly stated as a numerical count of cases or patients in the provided text. The document mentions "a retrospective study" was conducted and "each case output from the JBS-LVO device was compared with a ground truth."
• Data Provenance: Retrospective study. The origin of the data (e.g., country of origin) is not explicitly mentioned for the test set, but it states that "the images used to train the algorithm were sourced from datasets that included equipment from various manufacturers, such as Siemens, Philips, Toshiba, and GE", implying a diverse source for the overall dataset.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

• Number of Experts: Three (two initial ground truthers, with a third intervening in cases of disagreement).
• Qualifications of Experts: All truthers were US board-certified neuroradiologists.

4. Adjudication Method for the Test Set

• Adjudication Method: 2+1 adjudication. The ground truth was determined by two ground truthers, with a third ground truther intervening in cases of disagreement.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

• MRMC Study: No, an MRMC comparative effectiveness study was not conducted. The document describes a "standalone performance evaluation" of the algorithm only.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

• Standalone Performance Study: Yes, a standalone performance evaluation of the algorithm without human-in-the-loop performance was conducted. The text states: "The performance of the device's AI algorithms was validated in a standalone performance evaluation, utilizing an independent dataset different from the one used for algorithm training." and "JLK, Inc. performed a standalone performance with the §892.2080 special controls to show acceptance of the clinical performance of the JBS-LVO module."

7. The Type of Ground Truth Used

• Ground Truth Type: Expert consensus. Specifically, ground truth was "established by US board-certified neuro-radiologists."

8. The Sample Size for the Training Set

• Training Set Sample Size: Not explicitly stated as a numerical count in the provided text. The document refers to it as "datasets."

9. How the Ground Truth for the Training Set Was Established

• Training Set Ground Truth: The training data was "labeled by trained radiologists to identify the presence of LVO." The specific number or adjudication method for these "trained radiologists" is not detailed, but it implies expert labeling.

Ask a specific question about this device

Rapid is an image processing software package to be used by trained professionals, including but not limited to physicians (medical analysis and decision making) and medical technicians (administrative case processing). The software runs on a standard off-the-shelf computer or a virtual platform, such as VMware, and can be used to perform image viewing, processing, and analysis of images. Data and images are acquired through DICOM compliant imaging devices. Rapid is indicated for use in Adults only.

Rapid provides both viewing and analysis capabilities for functional and dynamic imaging datasets acquired with CT, CT Perfusion (CTP), CT Angiography (CTA), C-arm CT Perfusion and MRI including a Diffusion Weighted MRI (DWI) Module and a Dynamic Analysis Module (dynamic contrast-enhanced imaging data for MRI, CT, and C-arm CT).

Rapid C-arm CT Perfusion can be used to qualitatively assess cerebral hemodynamics in the angiography suite.

The CT analysis includes NCCT maps showing areas of hypodense and hyperdense tissue.

The DWI Module is used to visualize local water diffusion properties from the analysis of diffusion - weighted MRI data.

The Dynamic Analysis Module is used for visualization and analysis of dynamic imaging data, showing properties of changes in contrast over time. This functionality includes calculation of parameters related to tissue flow (perfusion) and tissue blood volume.

Rapid CT Perfusion and Rapid MR Perfusion can be used by physicians to aid in the selection of acute stroke patients (with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery). Instructions for the use of contrast agents for this indication can be found in Appendix A of the User's Manual. Additional information for safe and effective drug use is available in the product-specific iodinated CT and gadolinium-based MR contrast drug labeling.

In addition to the Rapid imaging criteria, patients must meet the clinical requirements for thrombectomy, as assessed by the physician, and have none of the following contraindications or exclusions:

· Bolus Quality: absent or inadequate bolus.

· Patient Motion: excessive motion leading to artifacts that make the scan technically inadequate.

· Presence of hemorrhage.

· C-Arm CTP is not to be used in the Rapid Thrombectomy indication criteria, other modalities should be consulted.

Cautions:

· C-Arm CTP provides qualitative data only, review other modalities prior to diagnosis. CBV and CBT are not absolute and CBT, CBV, MTT and Tmax are supported for qualitative interpretation of the perfusion maps only.

Rapid is a software package that provides for the visualization and study of changes in tissue using digital images captured by diagnostic imaging systems including CT (Computed Tomography) and MRI (Magnetic Image Resonance), as an aid to physician diagnosis.

Rapid can be installed on a customer's Server or it can be accessed online as a virtual system. It provides viewing, quantification, analysis and reporting capabilities.

Rapid works with the following types of (DICOM compliant) medical image data:

• CT (Computed Tomography)
• MRI(Magnetic Image Resonance) ●

Rapid acquires (DICOM compliant) medical image data from the following sources:

• . DICOM file
• DICOM CD-R ●
• Network using DICOM protocol. ●

Rapid provides tools for performing the following types of analysis:

• selection of acute stroke patients for endovascular thrombectomy ●
• volumetry of thresholded maps
• time intensity plots for dynamic time courses
• measurement of mismatch between labeled volumes on co-registered image ● volumes
• large vessel density. ●

Rapid is a Software as a Medical Device (SaMD) consisting of one or more Rapid Servers (dedicated or virtual). The Rapid Server is an image processing engine that connects to a hospital LAN, or inside the Hospital Firewall. It can be a dedicated Rapid Server or a VM Rapid appliance, which is a virtualized Rapid Server that runs on a dedicated server.

Rapid is designed to streamline medical image processing tasks that are time consuming and fatiguing in routine patient workup. Once Rapid is installed it operates with minimal user interaction. Once the CT [NCCT, CT, CTA, C-arm CT(CBCT)] or MR (MR, MRA) data are acquired, the CT or MRI console operator selects Rapid as the target for the DICOM images, and then the operator selects which study/series data to be sent to Rapid. Based on the type of incoming DICOM data, Rapid will identify the data set scanning modality and determine the suitable processing module. The Rapid Platform is a central unit which coordinates the execution image processing modules which support various analysis methods used in clinical practice today:

• Rapid CTP/MRP/C-arm CTP, DWI, Dynamic Analysis (Original: K121447, Updated ● with K172477, K182130, K213165, K233512 and K233582)
• Rapid CTA (K172477) ●
• Rapid ASPECTS (K200760, K232156)
• Rapid ICH (K193087, K221456)
• Rapid LVO (K200941, K221248)
• Rapid NCCT Stroke (K222884)
• . Rapid RV/LV (K223396)
• Rapid PETN (K220499)
• Rapid ANRTN (K230074) ●
• Rapid SDH (K232436) ●

The iSchemaView Server is a dedicated server that provides a central repository for Rapid data. All iSchemaView Server data is stored on encrypted hard disks. It also provides a user interface for accessing Rapid data. It connects to a firewalled Data Center Network and has its own firewall for additional cyber/data security. The iSchemaView Server connects to one or more Rapid Servers via WAN. Available types of connection include VPN (Virtual Private Network - RFC2401 and RFC4301 Standards) Tunnel and SSH (Secure Shell).

The provided text describes the iSchemaView Rapid device, an image processing software package. The document focuses on its 510(k) submission (K233582) and demonstrates its substantial equivalence to a previously cleared predicate device (K213165). The new submission primarily extends the device's functionality to include C-arm CT for qualitative cerebral hemodynamics assessment and qualitative analysis of perfusion parameters.

Here's an analysis of the acceptance criteria and the study that proves the device meets them, based on the provided text:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly present a "table of acceptance criteria" with corresponding "reported device performance" in the format typically used for performance studies with specific metrics and thresholds (e.g., sensitivity, specificity, accuracy). Instead, it states that the device was validated to provide "accurate representation of key processing parameters" and "met all design requirements and specifications."

The key performance claims and their validation are described qualitatively:

2. Sample size used for the test set and the data provenance

The document states that iSchemaView conducted "extensive phantom validation testing" and "software verification and validation testing of the Rapid system" using "the use of phantoms and case data." However, it does not specify the sample size for the test set (number of phantoms or cases).

The data provenance is stated as:

• Phantoms: Used for characterizing perfusion imaging performance.
• Case Data: Used for validating the Rapid System performance.

The document does not explicitly mention the country of origin of the data or whether it was retrospective or prospective.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

The document does not specify the number of experts used to establish ground truth for the test set or their specific qualifications. It mentions that the device is "to be used by trained professionals, including but not limited to physicians (medical analysis and decision making) and medical technicians (administrative case processing)" and that "Rapid C-arm CT Perfusion can be used to qualitatively assess cerebral hemodynamics in the angiography suite." While this indicates the intended users, it does not explicitly detail the experts involved in establishing ground truth for the validation studies.

4. Adjudication method for the test set

The document does not mention any adjudication method (e.g., 2+1, 3+1) used for establishing ground truth in the test set.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

The document does not describe an MRMC comparative effectiveness study where human readers' performance with and without AI assistance was evaluated. The current submission focuses on demonstrating substantial equivalence and the performance of the device itself (including its new feature for C-arm CT) rather than its direct comparative effectiveness with human readers.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The provided text only discusses "extensive phantom validation testing" and "software verification and validation testing." The results presented ("accurate representation of key processing parameters," "met all design requirements and specifications," and "comparable with small biases") appear to be from an algorithm-only (standalone) performance assessment, particularly for the software's ability to process and represent data from phantoms and cases, and the comparability of C-arm CT processing to conventional CT. There is no mention of human-in-the-loop performance in the context of these validation studies.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

For the "phantom validation testing," the ground truth would inherently be known physical and temporal parameters designed into the phantoms.
For the "case data," the document does not explicitly state the type of ground truth. Given the nature of a software processing and analysis system, it likely relies on a combination of:

• Established interpretations from other modalities or clinical diagnoses, particularly for "selecting acute stroke patients."
• Quantitative measurements derived from advanced imaging, which the software aims to replicate or analyze.

8. The sample size for the training set

The document does not specify the sample size for the training set. It details the device's functionality and validation rather than its development or machine learning training specifics.

9. How the ground truth for the training set was established

Since the document does not mention the sample size for the training set, it also does not describe how the ground truth for the training set was established. The focus is on the validation of the developed software, which includes algorithms, some of which may be AI/ML-based as indicated by "Mixed Traditional and AI/ML" under Software in Table 1 (page 10). However, the specifics of ML model training, including data and ground truth establishment, are not detailed in this summary.

Ask a specific question about this device

Rapid is an image processing software package to be used by trained professionals,including but not limited to physicians and medical technicians. The software runs ona standard off-the-shelf computer or a virtual platform, such as VMware, and can be used to perform image viewing, processing and analysis of images. Data and images are acquired through DICOM compliant imaging devices.

Rapid provides both viewing and analysis capabilities for functional and dynamic imaging datasets acquired with CT Perfusion (CTP). CT Angiography (CTA), and MRI including a Diffusion Weighted MRI (DWI) Module and a Dynamic Analysis Module (dynamic contrast-enhanced imaging data for MRI and CT).

The CT analysis includes NCCT maps showing areas of hypodense and hyperdense tissue.

The DWI Module is used to visualize local water diffusion properties from the analysis of diffusion weighted MRI data.

The Dynamic Analysis Module is used for visualization and analysis of dynamic imaging data, showing properties of changes in contrast over time. This functionality includes calculation of parameters related to tissue flow (perfusion) and tissue blood volume.

Rapid CT-Perfusion and Rapid MR-Perfusion can be used by physicians to aid in the selection of acute stroke patients (with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery)Instructions for the use of contrast agents for this indication can be found in Appendix A of the User's Manual. Additional information for safe and effective drug use is available inthe product-specific iodinated CT and gadolinium-based MR contrast drug labeling.

In addition to the Rapid imaging criteria, patients must meet the clinical requirements for thrombectomy, as assessed by the physician, and have none of the following contraindications or exclusions:

• · Bolus Quality: absent or inadequate bolus.
• · Patient Motion: excessive motion leading to artifacts that make the scan technically inadequate
• Presence of hemorrhage

Rapid is a software package that provides for the visualization and study of changes in tissue using digital images captured by diagnostic imaging systems including CT (Computed Tomography) and MRI (Magnetic Image Resonance), as an aid to physician diagnosis. Rapid can be installed on a customer's Server or it can be accessed online as a virtual system. It provides viewing, quantification, analysis and reporting capabilities.

Rapid is a Software as a Medical Device (SaMD) consisting of one or more Rapid Servers (dedicated or virtual) in on-premises or hybrid (on-premises/cloud) configurations. The Rapid Server is an image processing engine that connects to a hospital LAN, or inside the Hospital Firewall in the on-premises configuration or in conjunction with a secure link to the cloud in the hybrid configuration. It can be a dedicated Rapid Server or a VM Rapid appliance, which is a virtualized Rapid Server that runs on a dedicated server.

Rapid is designed to streamline medical image processing tasks that are time consuming and fatiguing in routine patient workup. Once Rapid is installed it operates with minimal user interaction. Once the CT (NCCT, CT, CTA) or MR (MR, MRA) data are acquired, the CT or MRI console operator selects Rapid as the target for the DICOM images, and then the operator selects which study/series data to be sent to Rapid. Based on the type of incoming DICOM data. Rapid will identify the data set scanning modality and determine the suitable processing module. The Rapid platform is a central control unit which coordinates the execution image processing modules which support various analysis methods used in clinical practice today.

Here's an analysis of the provided text to fulfill your request, noting that the document is an FDA 510(k) clearance letter and summary, which typically focuses on demonstrating substantial equivalence to a predicate device rather than presenting a detailed de novo device performance study. Therefore, some of the requested information (like specific effect sizes from MRMC studies or detailed ground truth establishment for a training set) might not be explicitly present if the submission didn't require entirely new clinical performance data for clearance.

Key Observation from the Document:
The document (K233512) is a 510(k) summary for iSchemaView Rapid (6.0), claiming substantial equivalence to a previously cleared predicate device, Rapid (K213165). The primary change appears to be an "extension of installation in a hybrid configuration (on-premises and hybrid)." This implies that extensive new clinical performance studies for the core functionality may not have been required, as the device is deemed "as safe and effective as the previously cleared Rapid (K213165) with an extension of installation in a hybrid configuration."

Given this, the "acceptance criteria" and "study that proves the device meets the acceptance criteria" are largely framed around demonstrating equivalence to the predicate and ensuring the new configuration doesn't introduce new safety or effectiveness concerns.

Acceptance Criteria and Device Performance (Based on the provided document)

Since this is a 510(k) submission for substantial equivalence based on a predicate, the "acceptance criteria" are implied to be that the device performs equivalently to the predicate and any new features (like hybrid configuration) do not negatively impact safety or effectiveness. The document highlights software verification and validation as the primary means of demonstrating compliance.

1. Table of Acceptance Criteria and Reported Device Performance

• Image viewing, processing, and analysis of CT/MRI images for functional and dynamic imaging datasets.
• Specific modules: CT-Perfusion, MR-Perfusion, DWI, Dynamic Analysis, NCCT maps (hypodense/hyperdense tissue), CTA.
• Aid in selection of acute stroke patients (with known occlusion of intracranial ICA or proximal MCA).
• Calculation of parameters related to tissue flow (perfusion) and tissue blood volume. | "Rapid has the same intended use and similar indications, technological characteristics and principles of operation as its predicate devices."
  "Rapid is as safe and effective as the previously cleared Rapid (K213165) with an extension of installation in a hybrid configuration..." |
  | Technical Compliance:
• DICOM compliance.
• Operates on standard off-the-shelf computers or virtual platforms.
• Handles DICOM medical image data (CT, MRI) from various sources.
• Secure communication protocols (SMTP with security extensions, VPN, SSH). | "Rapid complies with DICOM (Digital Imaging and Communications in Medicine) - Developed by the American College of Radiology and the National Electrical Manufacturers Association. NEMA PS 3.1 - 3.20."
  "Rapid is a DICOM-compliant PACS software..."
  "Rapid runs on standard 'off-the-shelf' computer and networking hardware."
  "Rapid generally connects to the infrastructure of the medical partner... Rapid uses a SMTP protocol with security extensions to provide secure communications."
  "Available types of connection include VPN (Virtual Private Network - RFC2401 and RFC4301 Standards) Tunnel and SSH (Secure Shell)." |
  | Performance Accuracy & Reliability:
• Accurate representation of key processing parameters.
• Handles clinically relevant parameters and perturbations.
• Meets all design requirements and specifications. | "iSchemaView conducted extensive performance validation testing and software verification and validation testing of the Rapid system."
  "This performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software."
  "Software performance, validation and verification testing demonstrated that the Rapid system met all design requirements and specifications."
  "The Rapid System performance has been validated with phantom and case data." |
  | Safety & Effectiveness (no new issues compared to predicate):
• Compliance with QSR (21 CFR Part 820.30).
• Risk management (EN ISO 14971:2019).
• Software lifecycle processes (IEC 62304:2016).
• Usability engineering (IEC 62366:2015). | "Rapid has been designed, verified and validated in compliance with 21 CFR, Part 820.30 requirements. The device has been designed to meet the requirements associated with EN ISO 14971:2019 (risk management)."
  "Rapid raises no new issues of safety or effectiveness compared to Rapid (K2131650), as demonstrated by the testing conducted with Rapid." |

2. Sample Size Used for the Test Set and Data Provenance

The document mentions "The Rapid System performance has been validated with phantom and case data." However, it does not specify the sample size for the test set of "case data" or "phantom data", nor does it specify the country of origin or whether the data was retrospective or prospective. For a 510(k), particularly one proving substantial equivalence to a predicate, new large-scale clinical studies are not always required if software verification and validation suffice, as implied here.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

The document states, "The primary users of Rapid software are medical imaging professionals who analyze tissue using CT or MRI images." However, it does not specify the number of experts used to establish ground truth for the test set, nor does it provide their specific qualifications (e.g., number of years of experience, specific board certifications). It only generically refers to "trained professionals, including but not limited to physicians and medical technicians."

4. Adjudication Method for the Test Set

The document does not specify any adjudication method (e.g., 2+1, 3+1) used for the test set.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

The document does not indicate that a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was done comparing human readers with AI vs. without AI assistance, nor does it state an effect size for such an improvement. The focus is on the device's standalone performance and its equivalence to the predicate.

6. If a Standalone Performance Study (Algorithm Only Without Human-in-the-Loop Performance) Was Done

Yes, the document implies that a standalone performance evaluation of the algorithm's core processing capabilities was conducted. It states: "iSchemaView conducted extensive performance validation testing and software verification and validation testing of the Rapid system. This performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software." This refers to the algorithm's performance in processing images and generating analyses.

7. The Type of Ground Truth Used

The document states, "The Rapid System performance has been validated with phantom and case data." This suggests that the ground truth for "phantom data" would be known physical or simulated values. For "case data," the document does not explicitly state the type of ground truth, such as expert consensus, pathology, or outcomes data. However, given the context of stroke patient selection, clinical outcomes or expert consensus on imaging findings would typically be relevant for such applications.

8. The Sample Size for the Training Set

The document does not provide any information regarding the sample size used for the training set. As this is a 510(k) for an updated version of an existing device, it's possible that the training data for the core AI components was part of earlier development and was not re-evaluated for this specific submission, or that detailed training data was not a required element for this type of substantial equivalence claim.

9. How the Ground Truth for the Training Set Was Established

The document does not provide any information on how the ground truth for the training set was established.

Ask a specific question about this device